Showing results (21-30 of 133) with videos related to
Sort By:
Pageof 14
Annals of Epidemiology|July 28, 2020
Partitioning of time trends in prevalence and mortality of bladder cancer in the United StatesIgor Akushevich, Arseniy P Yashkin, Brant A Inman, et al.Urologic Oncology|January 24, 2021
Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortageDominic C Grimberg, John Dudinec, Ankeet Shah, et al.Cancer|May 13, 2009
Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortalityBrant A Inman, Viet-Tan Tran, Yves Fradet, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 14, 2019
Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancerLaura Meleis, Russell Moore, Brant A Inman, et al.European Urology Focus|July 21, 2017
Reporting Bias Leading to Discordant Venous Thromboembolism Rates in the United States Versus Non-US Countries Following Radical Cystectomy: A Systematic Review and Meta-analysisJoseph J Fantony, Ajay Gopalakrishna, Megan Van Noord, et al.BJU International|February 9, 2012
An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over timeBrant A Inman, Jingyu Zhang, Nilay D Shah, et al.The Journal of Urology|October 9, 2003
Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patientsBrant A Inman, François Harel, Rabi Tiguert, et al.European Urology Oncology|August 15, 2019
The Cost to Medicare of Bladder Cancer CareFrank A Sloan, Arseniy P Yashkin, Igor Akushevich, et al.Urologic Oncology|November 26, 2019
Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancerFrank A Sloan, Arseniy P Yashkin, Igor Akushevich, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
Atezolizumab: A PD-L1-Blocking Antibody for Bladder CancerBrant A Inman, Thomas A Longo, Sundhar Ramalingam, et al.Pageof 14